Name:	tsro_CollaborativeArrangementsCostSharingReceivable
Namespace Prefix:	tsro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Period from date of first commercial sale of product that the collaborative agreement expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

No definition available.

Name:	tsro_CollaborativeArrangementsExpirationPeriod
Namespace Prefix:	tsro_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Collaborative arrangements termination period.

No definition available.

Name:	tsro_CollaborativeArrangementsTerminationPeriod
Namespace Prefix:	tsro_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Amount of deferred revenue allocated to a specific arrangement.

No definition available.

Name:	tsro_DeferredRevenueAllocation
Namespace Prefix:	tsro_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Amount of cost-sharing external costs reimbursable.

No definition available.

Name:	tsro_ExternalCostsReimbursable
Namespace Prefix:	tsro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The number of clinical or regulatory milestones included in the transaction price of the agreement.

No definition available.

Name:	tsro_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
Namespace Prefix:	tsro_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Period of time within which the Company agreed to provide the counterparty with electronic copies of certain know-how relating to development of product.

No definition available.

Name:	tsro_NumberOfDaysToProvideElectronicCopiesOfCertainKnowHowRelatingToDevelopmentOfProduct
Namespace Prefix:	tsro_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

The number of novel, discovery-stage immuno-oncology programs the entity has the option to negotiate for licenses with counterparty.

No definition available.

Name:	tsro_NumberOfNovelDiscoveryStageImmunoOncologyProgramsUnderOptionToNegotiateLicenses
Namespace Prefix:	tsro_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

Represents the cash outflow for acquisitions of product licenses and milestone payments during the reporting period.

No definition available.

Name:	tsro_PaymentsToAcquireProductLicenseAndMilestonePayments
Namespace Prefix:	tsro_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Represents the period by which transaction price will be recognized as revenue.

No definition available.

Name:	tsro_PeriodByWhichTransactionPriceWillBeRecognizedAsRevenue
Namespace Prefix:	tsro_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Represents the period for recognizing performance obligation.

No definition available.

Name:	tsro_PeriodForRecognizingPerformanceObligation
Namespace Prefix:	tsro_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Represents the potential payment that may be received upon achievement of specified milestones per agreement.

No definition available.

Name:	tsro_PotentialPaymentForAchievementOfSpecifiedMilestones
Namespace Prefix:	tsro_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Represents the threshold period within which transaction price is recognized as revenue after entering into collaboration agreement.

No definition available.

Name:	tsro_ThresholdPeriodWithinWhichTransactionPriceRecognizedAsRevenue
Namespace Prefix:	tsro_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

No definition available.

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d),(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Name:	us-gaap_LicenseAndServicesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Name:	us-gaap_LicensesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Cash received from licensees for license fees during the current period.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3536-108585

Name:	us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275

Name:	us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Name:	us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

The fair value of stock issued in noncash financing activities.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Name:	us-gaap_StockIssued1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Name:	us-gaap_CounterpartyNameAxis=tsro_JiangsuHengruiMedicineCo.Ltd.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_CounterpartyNameAxis=tsro_ZaiLabShanghaiCo.LtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_CounterpartyNameAxis=tsro_JanssenBiotechInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=tsro_ResearchAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_CounterpartyNameAxis=tsro_MerckSharpDohmeCorpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_StatementScenarioAxis=tsro_AchievementOfClinicalMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_StatementScenarioAxis=tsro_AchievementOfRegulatoryAndSalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_StatementScenarioAxis=tsro_AchievementOfClinicalRegulatoryAndSalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_ProductOrServiceAxis=tsro_TechnicalAssistancePerformanceObligationServiceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_ProductOrServiceAxis=tsro_InitialManufacturingSupplyServiceMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_NonsoftwareLicenseArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=tsro_JointCommitteePerformanceObligationArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=tsro_CollaborationAndExclusiveLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_TypeOfArrangementAxis=tsro_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Name:	us-gaap_StatementScenarioAxis=tsro_AchievementOfSubmissionOfClinicalTrialApplicationWithChinaFDaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: